Antibody drug conjugate
Patent Information
- Authority / Receiving Office
- FI · FI
- Patent Type
- Patents
- Current Assignee / Owner
- CHIA TAI TIANQING PHARMA GRP CO LTD
- Filing Date
- 2021-08-13
- Publication Date
- 2026-07-15
AI Technical Summary
Current antibody-drug conjugates face challenges in developing highly potent and low-toxic ADCs that can target a wide range of cancer indications, particularly due to the inefficiency of camptothecin derivatives like SN-38 in converting to their active form and the poor solubility of these drugs.
Development of a deuterated antibody-drug conjugate with a deuterated modification in the linker or cytotoxic drug moiety, specifically designed to target HER2-positive cancers, using a conjugate structure of Ab-(L-U)n where Ab is an antibody moiety, L is a linker moiety, and U is a cytotoxic drug moiety, with modifications such as K30E and F53Y mutations in the VH and VL regions, respectively, to enhance binding affinity and pharmacokinetic properties.
The deuterated antibody-drug conjugate demonstrates improved binding affinity and reduced toxicity, leading to enhanced therapeutic efficacy and increased safety, effectively targeting HER2-positive cancers with improved pharmacokinetic properties.